SPRB Earnings Date: Nov 9, 2026 (Estimated) — Spruce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SPRB's next earnings date?
Spruce Biosciences, Inc. (SPRB) is expected to report earnings on Monday, November 9, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$5.68 on revenue of $50.0M.
How did SPRB do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Spruce Biosciences, Inc. posted EPS of -$6.68 versus the -$5.79 estimate, a miss of 39.5%. Revenue was $0. The stock's 1-day post-earnings move was +1.4%.
How much does SPRB stock move after earnings?
SPRB beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.9% (up or down) in the day after earnings.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -5.79 | -6.68 | -39.46% | $0 | ❌ Miss | +1.42% | +13.87% | +17.11% |
| 2026-05-13 | Q1 2026 | -7.32 | -8.94 | -22.13% | $0 | ❌ Miss | +1.56% | -14.85% | -13.34% |
| 2026-03-09 | Q4 2025 | -12.86 | -36.25 | -181.88% | $0 | ❌ Miss | +11.17% | +7.50% | +11.24% |
| 2025-11-10 | Q3 2025 | -15.56 | -14.58 | +6.30% | $0 | ✅ Beat | -2.55% | -5.86% | -25.90% |
| 2025-08-14 | Q2 2025 | -20.25 | -3.50 | +82.72% | $0 | ✅ Beat | +0.00% | +0.00% | +12368.19% |
| 2025-04-15 | Q4 2024 | -0.20 | -0.57 | -185.00% | $697,000 | ❌ Miss | -58.02% | -58.78% | -75.00% |
| 2024-11-11 | Q3 2024 | -0.24 | -0.21 | +12.50% | $602,000 | ✅ Beat | -0.62% | -8.44% | +0.22% |
| 2024-08-12 | Q2 2024 | -0.30 | -0.22 | +26.67% | $1.6M | ✅ Beat | +3.88% | +12.52% | +12.52% |
Showing last 8 quarters.